A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Exclusion Criteria

• •Subjects will be excluded from the study if they present with any of the following:
• •1. Not a candidate for PCI
• •2. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding
• •3. Impaired hemostasis: known International Normalized Ratio (INR) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL), or history of thrombocytopenia or neutropenia associated with clopidogrel
• •4. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization
• •5. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
• •6. Receipt of clopidogrel dose exceeding maintenance dose (ie, \>75 mg) at any time in the 5 days preceding randomization
• •7. Inability to swallow study capsules
• •8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours \[applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients\]
• •Subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.